PUBLISHER: Polaris Market Research | PRODUCT CODE: 1786842
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1786842
U.S. Point of Care Lipid Test Market Size, Share, Trends, Industry Analysis Report By Product (Instruments, Consumables), By Application, By Disease Indication, By End Use- Market Forecast, 2025-2034
The U.S. point of care (POC) lipid test market size is expected to reach USD 553.25 million by 2034, according to a new study by Polaris Market Research. The report "U.S. Point of Care Lipid Test Market Size, Share, Trends, Industry Analysis Report By Product (Instruments, Consumables), By Application, By Disease Indication, By End Use- Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
A point of care (POC) lipid test is a diagnostic tool used to measure lipid levels such as total cholesterol, HDL, LDL, and triglycerides, directly at the site of patient care. It provides rapid results from a small blood sample, often within minutes, without needing a central laboratory.
The U.S. healthcare system is increasingly focusing on preventive care to reduce long-term costs and improve patient outcomes. Regular cholesterol screening is a key part of this approach, especially for at-risk groups such as the elderly or those with diabetes. Point of care lipid tests support this preventive model by offering immediate results during routine visits. This eliminates the need for lab processing and encourages more frequent testing. Preventive care is propelling the U.S. POC lipid test market with wellness programs, employer-sponsored health checks, and government-supported initiatives promoting early detection.
Innovation in diagnostic services and technology is rapidly transforming point of care lipid testing in the U.S. Modern lipid testing devices offer better accuracy, faster results, and user-friendly interfaces, making them ideal for various healthcare settings. Bluetooth-enabled meters, smartphone integration, and compact portable analyzers have increased the utility and convenience of POC lipid tests. Companies such as Abbott and Roche are continuously launching improved products tailored to the U.S. These advancements attract both healthcare providers and patients, further accelerating adoption across clinical and nonclinical environments, thereby driving the POC lipid test market growth.
U.S. Point of Care Lipid Test Market Report Highlights
In 2024, the consumables segment dominated with the largest share due to its recurring demand and widespread use.
The hypertriglyceridemia segment is expected to experience significant growth during the forecast period, driven by factors such as obesity, high sugar intake, sedentary lifestyles, and poor diet.
A few key market players are Abbott Laboratories; Callegari Srl; F. Hoffmann-La Roche Ltd.; Menarini Group; MiCoBio; Nova Biomedical; SD Biosensor, Inc.; Sinocare Inc.; and VivaChek Biotech (Hangzhou) Co., Ltd.
Polaris Market Research has segmented the U.S. point of care lipid test market report on the basis of product, application, disease indication, end use, and region:
By Product (Revenue - USD Million, 2020-2034)
Instruments
Consumables
By Application (Revenue - USD Million, 2020-2034)
Hyperlipidemia
Hypertriglyceridemia
Tangier Disease
Hyperlipoproteinemia
Familial Hypercholesterolemia
Others
By Disease Indication (Revenue - USD Million, 2020-2034)
Lipid and Lipoprotein Disorders
Atherosclerosis
Liver and Renal Diseases
Diabetes Mellitus
Others
By End Use (Revenue - USD Million, 2020-2034)
Hospitals
Clinics
Research and Diagnostic Laboratories
Others
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. U.S. Point of Care Lipid Test Market Insights
- 4.1. Point of Care Lipid Test Market - Market Snapshot
- 4.2. Point of Care Lipid Test Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Incidence of Obesity and Diabetes
- 4.2.1.2. Rising Prevalence of Cardiovascular Diseases
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Initial Investment
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Point of Care Lipid Test Market Trends
- 4.6. Value Chain Analysis
5. U.S. Point of Care Lipid Test Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. U.S. Point of Care Lipid Test Market, by Product, 2020-2034 (USD million)
- 5.3. Instruments
- 5.3.1. U.S. Point of Care Lipid Test Market, by Instruments, 2020-2034 (USD million)
- 5.4. Consumables
- 5.4.1. U.S. Point of Care Lipid Test Market, by Consumables 2020-2034 (USD million)
6. U.S. Point of Care Lipid Test Market, by Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. U.S. Point of Care Lipid Test Market, by Application, 2020-2034 (USD million)
- 6.3. Hyperlipidemia
- 6.3.1. U.S. Point of Care Lipid Test Market, by Hyperlipidemia 2020-2034 (USD million)
- 6.4. Hypertriglyceridemia
- 6.4.1. U.S. Point of Care Lipid Test Market, by Hypertriglyceridemia 2020-2034 (USD million)
- 6.5. Tangier Disease
- 6.5.1. U.S. Point of Care Lipid Test Market, by Tangier Disease, 2020-2034 (USD million)
- 6.6. Hyperlipoproteinemia
- 6.6.1. U.S. Point of Care Lipid Test Market, by Hyperlipoproteinemia, , 2020-2034 (USD million)
- 6.7. Familial Hypercholesterolemia
- 6.7.1. U.S. Point of Care Lipid Test Market, by Familial Hypercholesterolemia, 2020-2034 (USD million)
- 6.8. Others
- 6.8.1. U.S. Point of Care Lipid Test Market, by Others, 2020-2034 (USD million)
7. U.S. Point of Care Lipid Test Market, by Disease Indication
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. U.S. Point of Care Lipid Test Market, by Medical Biotechnology, 2020-2034 (USD million)
- 7.3. Lipid and Lipoprotein Disorders
- 7.3.1. U.S. Point of Care Lipid Test Market, by Lipid and Lipoprotein Disorders, 2020-2034 (USD million)
- 7.4. Atherosclerosis
- 7.4.1. U.S. Point of Care Lipid Test Market, by Atherosclerosis, 2020-2034 (USD million)
- 7.5. Liver and Renal Diseases
- 7.5.1. U.S. Point of Care Lipid Test Market, by Liver and Renal Diseases, by Region, 2020-2034 (USD million)
- 7.6. Diabetes Mellitus
- 7.6.1. U.S. Point of Care Lipid Test Market, by Diabetes Mellitus, 2020-2034 (USD million)
- 7.7. Others
- 7.7.1. U.S. Point of Care Lipid Test Market, by Others, 2020-2034 (USD million)
8. U.S. Point of Care Lipid Test Market, by End Use
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. U.S. Point of Care Lipid Test Market, by End Use, 2020-2034 (USD million)
- 8.3. Hospitals
- 8.3.1. U.S. Point of Care Lipid Test Market, by Hospitals, 2020-2034 (USD million)
- 8.4. Clinics
- 8.4.1. U.S. Point of Care Lipid Test Market, by Clinics, 2020-2034 (USD million)
- 8.5. Research and Diagnostic Laboratories
- 8.5.1. U.S. Point of Care Lipid Test Market, by Research and Diagnostic Laboratories, 2020-2034 (USD million)
- 8.6. Others
- 8.6.1. U.S. Point of Care Lipid Test Market, by Others, 2020-2034 (USD million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Abbott Laboratories
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Callegari Srl
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. F. Hoffmann-La Roche Ltd.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Menarini Group
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. MiCoBio
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Nova Biomedical
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. SD Biosensor, Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Sinocare Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. VivaChek Biotech (Hangzhou) Co., Ltd.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
List of Tables:
- Table 1 U.S. Point of Care Lipid Test Market, by Product, 2020-2034 (USD million)
- Table 2 U.S. Point of Care Lipid Test Market, by Application, 2020-2034 (USD million)
- Table 3 U.S. Point of Care Lipid Test Market, by Disease Indication, 2020-2034 (USD million)
- Table 4 U.S. Point of Care Lipid Test Market, by End Use, 2020-2034 (USD million)
List of Figures:
- Figure 1. U.S. Point of Care Lipid Test Market, 2020-2034 (USD million)
- Figure 2. Integrated Ecosystem
- Figure 3. Research Methodology: Top-Down & Bottom-Up Price
- Figure 4. Porter's Five Forces
- Figure 5. Market by Product
- Figure 6. U.S. Point of Care Lipid Test Market, by Product, 2024 & 2034 (USD million)
- Figure 7. Market by Application
- Figure 8. U.S. Point of Care Lipid Test Market, by Application, 2024 & 2034 (USD million)
- Figure 9. Market by Disease Indication
- Figure 10. U.S. Point of Care Lipid Test Market, by Disease Indication, 2024 & 2034 (USD million)
- Figure 11. Market by End Use
- Figure 12. U.S. Point of Care Lipid Test Market, by End Use, 2024 & 2034 (USD million)
- Figure 13. U.S. Point of Care Lipid Test Market Assessment, By Geography, 2020-2034 (USD million)
- Figure 14. Strategic Analysis - U.S. Point of Care Lipid Test Market
